A detailed history of Cito Capital Group, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Cito Capital Group, LLC holds 1,540 shares of REGN stock, worth $1.28 Million. This represents 0.63% of its overall portfolio holdings.

Number of Shares
1,540
Previous 1,040 48.08%
Holding current value
$1.28 Million
Previous $1 Million 61.74%
% of portfolio
0.63%
Previous 0.41%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$883.2 - $1071.19 $441,600 - $535,595
500 Added 48.08%
1,540 $1.62 Million
Q2 2023

Aug 14, 2023

SELL
$700.03 - $830.35 $4,900 - $5,812
-7 Reduced 0.67%
1,040 $747,000
Q1 2023

May 15, 2023

BUY
$680.49 - $826.97 $4,763 - $5,788
7 Added 0.67%
1,047 $860,000
Q3 2022

Nov 14, 2022

SELL
$573.97 - $724.32 $573,970 - $724,320
-1,000 Reduced 49.02%
1,040 $716,000
Q2 2022

Aug 15, 2022

SELL
$548.35 - $738.84 $274,175 - $369,420
-500 Reduced 19.69%
2,040 $1.21 Million
Q4 2021

Feb 14, 2022

SELL
$543.48 - $670.97 $304,348 - $375,743
-560 Reduced 18.06%
2,540 $1.6 Million
Q3 2021

Nov 10, 2021

SELL
$574.03 - $680.96 $287,015 - $340,480
-500 Reduced 13.89%
3,100 $1.88 Million
Q3 2019

Nov 14, 2019

SELL
$273.46 - $318.39 $41,019 - $47,758
-150 Reduced 4.0%
3,600 $999,000
Q2 2019

Aug 14, 2019

BUY
$299.6 - $414.82 $29,960 - $41,482
100 Added 2.74%
3,750 $1.17 Million
Q3 2018

Nov 13, 2018

BUY
$351.14 - $408.51 $52,671 - $61,276
150 Added 4.29%
3,650 $1.48 Million
Q2 2018

Jul 03, 2018

BUY
$284.6 - $344.99 $284,600 - $344,990
1,000 Added 40.0%
3,500 $1.21 Million
Q4 2017

Feb 12, 2018

BUY
$358.63 - $469.95 $358,630 - $469,950
1,000 Added 66.67%
2,500 $0
Q3 2017

Nov 13, 2017

BUY
$431.38 - $504.0 $647,070 - $756,000
1,500
1,500 $0

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $88.9B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Cito Capital Group, LLC Portfolio

Follow Cito Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cito Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cito Capital Group, LLC with notifications on news.